Feasibility of weekly patient-reported symptom monitoring using patients' own smartphones in outpatient cancer chemotherapy: the SMART-PRO study - Summary - MDSpire

Feasibility of weekly patient-reported symptom monitoring using patients' own smartphones in outpatient cancer chemotherapy: the SMART-PRO study

  • By

  • Yutaka Sugawara

  • Momoko Kobayashi

  • Eri Mannoji

  • Tomoya Saika

  • Yuki Kado

  • Michiko Yamazaki

  • Tohru Takebe

  • Hajime Higuchi

  • June 8, 2026

  • 0 min

Share

Objective:

To evaluate the feasibility of weekly ePRO monitoring of adverse events in outpatients receiving chemotherapy using a BYOD approach.

Key Findings:
  • Weekly ePRO response rates ranged from 75% to 93%, remaining above 75% for patients aged ≥70 years.
  • Pain-related items were the most frequent triggers for alerts, followed by numbness, rash, fatigue, and skin disorders.
  • EORTC QLQ-C30 global health status score showed a numerical increase from baseline to week 6 and week 12.
Interpretation:

The study indicates that BYOD-based ePRO monitoring is feasible in routine outpatient oncology care, including among older adults.

Limitations:
  • The study had a small sample size and was conducted at a single site.
  • No sample size calculation was performed, limiting generalizability.
Conclusion:

This study provides preliminary evidence for the implementation of BYOD-based ePRO monitoring in older adults undergoing chemotherapy.

Original Source(s)

Feasibility of weekly patient-reported symptom monitoring using patients' own smartphones in outpatient cancer chemotherapy: the SMART-PRO study

  • by Yutaka Sugawara, Momoko Kobayashi, Eri Mannoji, Tomoya Saika, Yuki Kado, Michiko Yamazaki, Tohru Takebe, Hajime Higuchi

  • June 8, 2026

Related Content

Rearming mesenchymal stem cells with engineering strategies to combat cancer

Granulocyte colony-stimulating factor-induced hypersensitivity reaction with leukocytosis in a pediatric germ cell tumor patient: a case report

Editorial: Autoantibodies in cancer: diagnostic, prognostic, and therapeutic potential